Probiotics in the Management of Inflammatory Bowel Diseases? (Q59120479)

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Probiotics and the management of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

A pilot trial of Saccharomyces boulardii in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Treatment of ulcerative colitis using fecal bacteriotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Lactobacillus GG in inducing and maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Saccharomyces boulardii in maintenance treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X

Safety of probiotics that contain lactobacilli or bifidobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01295.X